| Investment Opportunities in Women's Health Tro Kalayjian submits:The next several months will be an exciting time for the women’s health space, with several important events that may represent an opportunity for investors. Most notably, Pfizer (PFE) has completed data collection for it's 2186-patient study of Pristiq for the treatment of vasomotor symptoms, more commonly known as hot flashes. Wyeth, now part of Pfizer, began Pristiq's large trial in July of 2007, when the FDA asked Wyeth to produce a more comprehensive safety profile for Pristiq. At the time, Wyeth’s CEO, Robert Essner, said:Sales for Pristiq may top $2 billion, if Pristiq is approved for the "hot flash" indication.Complete Story » seekingalpha.com |
ERT Industry Poll and Sponsor Endorsement Confirms eC-SSRS is an Effective Method of Suicidality Monitoring in Clinical Trials (PR Newswire) ERT , Â a leading provider of centralized services to global pharmaceutical, biotechnology and medical device companies, announces that a recent survey of over 250 respondents reported that all clinicians polled found the Columbia Suicide Severity Rating Scale to be an effective method for prospectively monitoring suicidality. us.rd.yahoo.com |
Kensey Nash CEO Discusses F4Q10 Results - Earnings Call Transcript Kensey Nash Corp. (KNSY)F4Q10 (Qtr End 06/30/2010) Earnings CallAugust 23, 2010 9:00 am ETComplete Story » seekingalpha.com |
Diet Drugs Face FDA Scrutiny An FDA report cited safety issues with a proposed obesity drug, causing shares of Arena Pharmaceuticals to fall 40%, the latest setback for a field that once looked like a big pharmaceutical money-maker. online.wsj.com |
Sharps Compliance: PELLA-DRX™ - Video Sharps Compliance Inc. Repurposes Medical Waste into New Products feedproxy.google.com |